ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea
· Delayed Price · Currency is KRW 2,650.00
-25.00 (-0.93%)
At close: Apr 28, 2026
ADBiotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Net Income | -3,304 | -7,952 | -2,863 | 2,696 | -2,664 | Upgrade
|
| Depreciation & Amortization | 957.02 | 1,025 | 1,134 | 725.66 | 651.6 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 4.43 | - | - | -1.82 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1,503 | 421.96 | 2,590 | 45.21 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 650.25 | 4,263 | -3,023 | -390.47 | 24.16 | Upgrade
|
| Stock-Based Compensation | 81.52 | 97.85 | 80.28 | 172.9 | 74.91 | Upgrade
|
| Provision & Write-off of Bad Debts | -163.62 | 156.41 | -389.33 | 391.19 | 418.3 | Upgrade
|
| Other Operating Activities | -2,524 | -990.26 | -1,523 | -7,354 | 790.4 | Upgrade
|
| Change in Accounts Receivable | 1,139 | -1,338 | 660.74 | 1,197 | -2,135 | Upgrade
|
| Change in Inventory | 105.25 | -183.68 | 450.38 | -1,071 | -232.37 | Upgrade
|
| Change in Accounts Payable | 37.9 | 1,390 | -129.32 | -730.49 | 631.69 | Upgrade
|
| Change in Unearned Revenue | - | - | -49.75 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 198.64 | -986.07 | 3,378 | -4,274 | 257.49 | Upgrade
|
| Operating Cash Flow | -1,319 | -4,092 | 314.93 | -8,592 | -2,186 | Upgrade
|
| Capital Expenditures | -15,811 | -193.38 | -239.9 | -726.72 | -3,561 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.32 | 10.23 | - | - | 1.82 | Upgrade
|
| Cash Acquisitions | - | - | -1,381 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | -50 | - | - | Upgrade
|
| Investment in Securities | -6,254 | 1,322 | 4,094 | -1,106 | -1,198 | Upgrade
|
| Other Investing Activities | -20.33 | 102.61 | -15.86 | 34.09 | 256.9 | Upgrade
|
| Investing Cash Flow | -26,004 | 1,241 | 2,407 | -2,199 | -4,500 | Upgrade
|
| Short-Term Debt Issued | 6,000 | 1,100 | 1,560 | 2,057 | 1,000 | Upgrade
|
| Long-Term Debt Issued | 16,700 | 5,500 | 900 | - | 4,500 | Upgrade
|
| Total Debt Issued | 22,700 | 6,600 | 2,460 | 2,057 | 5,500 | Upgrade
|
| Long-Term Debt Repaid | -1,708 | -6,107 | -3,345 | -793.7 | -252.3 | Upgrade
|
| Net Debt Issued (Repaid) | 20,992 | 493.24 | -885.19 | 1,263 | 5,248 | Upgrade
|
| Issuance of Common Stock | 9,812 | - | - | 9,928 | 198.5 | Upgrade
|
| Other Financing Activities | -183.44 | -8.83 | - | -396.88 | -12.77 | Upgrade
|
| Financing Cash Flow | 30,620 | 484.41 | -885.19 | 10,794 | 5,433 | Upgrade
|
| Foreign Exchange Rate Adjustments | -22.65 | -10.24 | -1.56 | -19.03 | 9.41 | Upgrade
|
| Net Cash Flow | 3,275 | -2,376 | 1,836 | -16.18 | -1,243 | Upgrade
|
| Free Cash Flow | -17,130 | -4,285 | 75.03 | -9,319 | -5,747 | Upgrade
|
| Free Cash Flow Margin | -132.82% | -38.48% | 0.72% | -87.66% | -48.54% | Upgrade
|
| Free Cash Flow Per Share | -1425.77 | -468.82 | 8.21 | -924.41 | -747.71 | Upgrade
|
| Cash Interest Paid | 329.13 | 355.34 | 333.45 | 158.75 | 137.52 | Upgrade
|
| Cash Income Tax Paid | -0.18 | -0.92 | 5.51 | 21.24 | -13.28 | Upgrade
|
| Levered Free Cash Flow | -10,704 | -612.42 | -1,259 | -3,247 | -4,961 | Upgrade
|
| Unlevered Free Cash Flow | -9,569 | -186.13 | -992.12 | -3,170 | -4,880 | Upgrade
|
| Change in Working Capital | 1,481 | -1,119 | 4,310 | -4,879 | -1,479 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.